Martek kept at sell by Merrill

Merrill Lynch analyst David Munno maintained Martek Biosciences Corp. at a sell after the company reported third-quarter earnings per share and revenues that were roughly in line with expectations. Fourth-quarter guidance was 10% below consensus on revenue and 30% to 50% lower on earnings per share, according to the analyst. Merrill lowered its 2007 earnings per share to $0.69 from $0.72 and expects 2007 consensus to come down by at least 30% from $1.02. Shares of the Columbia, Md.-based pharmaceutical company were down $7.08, or 24.74%, at $21.54. (Nasdaq: MATK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.